問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Cardiovascular Diseases

Division of Endocrinology

Taichung Veterans General Hospital (在職)

Division of Pediatrics

更新時間：2023-09-19

林怡瑄
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

5Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林怡瑄

List

11Cases

2024-04-01 - 2028-08-03

Phase II

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
5Sites

Recruiting5Sites

2025-07-01 - 2028-12-31

Phase III

Active
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary Aldosteronism

  • Condition/Disease

    -Change from baseline in seated Systolic Blood Pressure (SBP) at Week 8 -Achieving normalization of the Renin Angiotensin Aldosterone system (RAAS) at week 8

  • Test Drug

    Baxdrostat

Participate Sites
6Sites

Recruiting6Sites

2018-08-01 - 2022-06-30

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2022-10-11 - 2024-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2022-12-01 - 2025-08-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2026-02-01 - 2029-02-24

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

2023-04-01 - 2032-12-31

Phase III

Active
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)

  • Condition/Disease

    Primary Prevention of Atherosclerotic Cardiovascular Disease

  • Test Drug

    KJX839 (Inclisiran)

Participate Sites
9Sites

Recruiting9Sites

2022-12-01 - 2025-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-10-11 - 2024-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2019-08-20 - 2022-03-01

Phase III

PIONEER 12 Multi-regional clinical trial: Efficacy and safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes mellitus treated with metformin

  • Condition/Disease

    Diabetes Mellitus, Type 2

  • Test Drug

    Semaglutide Tablets

Participate Sites
4Sites

Terminated4Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB